Prostocyclin and Endothelialopathy: A Phase 2 Trial

We're going to discuss the combat COVID trial, Phase 2 trial published in the Blue Journal in late November. That was a randomized placebo controlled trial investigating prostocyclin in mechanically ventilated patients infected with SARS-CoV-2 and with severe endothelialopathy. We did some preliminary studies showing that the dose of one nanogram per kilo per minute had no measurable effect on the blood pressure or on the playphiate inhibition. On the contrary, we found that biomarkers reflecting endothelium health or damage were appeared to be beneficially affected by prostocyClin.